Fabry Patients Show More Improvement with Fabrazyme Treatment, Study Finds
Treatment with Fabrazyme (agalsidase beta) leads to greater heart and biochemical improvements in Fabry disease patients than Replagal (agalsidase alfa), a study suggests. The study, “Agalsidase alfa versus agalsidase beta for the treatment of Fabry disease: an international cohort study,” appeared in the Journal of Medical Genetics. Fabry…